Search

Jeong-Hui Park,1 Tyler Prochnow,1 Jongwha Chang,2 Sun Jung Kim3– 5 1Texas A&M University, School of Public Health, College Station, TX, USA; 2Texas A&M University, Irma Lerma Rangel School of Pharmacy, College Station, TX, USA; 3Soonchunhyang University, College of Medical Sciences, Asan, Republic of Korea; 4Center for Healthcare Management Science, Soonchunhyang University, Asan, Republic of Korea; 5Department of Software Convergence, Soonchunhyang University, Asan, Republic of KoreaCorrespondence: Jongwha Chang, Texas A&M University, Irma Lerma Rangel School of Pharmacy, Department of Pharmaceutical Sciences, College Station, TX, 77843, USA, Email jc2345@tamu.edu Sun Jung Kim, Soonchunhyang University, College of Medical Science, Department of Health Administration and Management, Asan, Republic of Korea, Email sunjkim0623@sch.ac.krObjective: Atopic dermatitis (AD) is one of the common chronic diseases that occur in children and adolescents as a chronic relapsing pruritic inflammatory skin disease. This study investigated how AD is associated with stress and depressive symptoms in a large representative sample of adolescents in South Korea.Methods: The Korea Youth Risk Behavior Web-based Survey 2019 was used in this study (n = 57,069, weighted national estimates = 2,672,170). Multivariate logistic regression was used to determine significant associations between AD and mental health, measured by stress and depressive symptoms. Sub-group analysis was also conducted using various socio-economic variables.Results: Among the present sample, 6.5% of adolescents (n = 173,909) were diagnosed with AD in the past 12 months. After adjusting for other variables, AD diagnosis was associated with significantly higher odds of experiencing stress (OR = 1.43) and depressive symptoms (OR = 1.32) as compared to adolescents without AD. A similar trend is found in subgroup model analysis using socio-economic variables (ie, education levels, parent’s income levels, and

Sun Jung Kim,1– 3,* Mar Medina,4,* Rigoberto Delgado,5 Anastasia Miller,5 Jongwha Chang5 1Department of Health Administration and Management, College of Medical Science, Soonchunhyang University, Asan, Republic of Korea; 2Center for Healthcare Management Science, Soonchunhyang University, Asan, Republic of Korea; 3Department of Software Convergence, Soonchunhyang University, Asan, Republic of Korea; 4School of Pharmacy, University of Texas at El Paso, El Paso, TX, USA; 5Department of Healthcare Administration, College of Business, Texas Woman’s University, Denton, TX, USA*These authors contributed equally to this workCorrespondence: Jongwha Chang, Tel +1940-898-2899, Email jchang3@twu.eduPurpose: There is a lack of research focused on understanding the differences in the healthcare utilization of lung cancer patients between ethnic groups. This study aims to characterize disparities in healthcare utilization for Hispanic lung cancer patients compared to non-Hispanic patients.Methods: National Inpatient Sample was used to identify nationwide lung cancer patients (n=141,675, weighted n=702,878) from 2010 to 2014. We examined the characteristics of the study sample by race (Hispanic vs non-Hispanic) and its association with healthcare utilization, measured by discounted hospital charges and length of stay. Multivariate survey regression models were used to identify predictors by racial groups.Results: Among 702,878 lung cancer patients, 5.1% were Hispanic. Descriptive statistics showed that Hispanics have higher hospital charges and length of stay. Survey regression results also suggested that Hispanic lung cancer patients were associated with higher hospital charges (26.6%) and length of stay (3.5%) than non-Hispanic lung cancer patients. Subgroup analysis displayed a similar trend to the full model.Conclusion: Healthcare utilization disparities may exist for lung cancer Hispanic patients due to insurance status and early detection. Thus, o

Sun Jung Kim,1,2 Joo Hun Lee,3 Sulgi Kim,4 Shunichi Nakagawa,5 Heather Bertelson,6 Julia Lam,7 Ji Won Yoo6,7 1Department of Public Health, 2Institute of Health Services Research, Yonsei University College of Medicine, 3Department of Media and Communication, Hanyang University College of Social Sciences, Seoul, Republic of Korea; 4Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA; 5Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA; 6Department of Internal Medicine, Aurora Health Care, Milwaukee, WI, USA; 7Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Objective: To examine how drug therapy patterns for osteoporosis have changed after the Medicare Physician Fee Schedule (MPFS) reimbursement reduction in 2007, in relation to follow-up bone mineral density (BMD) testing status. Methods: We used a retrospective temporal shift design to examine changes in drug therapy patterns before (Phase 1: January 1, 2005–December 31, 2006) and after (Phase 2: July 1, 2007–June 30, 2009) the MPFS reimbursement reduction in 2007, Cleveland, OH, USA. Participants were osteoporotic older women in Phase 1 (n=1,340) and Phase 2 (n=1,437). The main outcomes were a) adherence, b) adjustment, c) occurrence of an extended gap, and d) restarting drug therapy after an extended gap. Follow-up BMD testing status by study phase and location were also analyzed. Results: BMD testing rates at physicians’ offices decreased from 64.5% in Phase 1 to 58.4% in Phase 2 (P=0.02); however, testing rates in hospital outpatient settings increased (from 20.8% to 24.5%). There were also decreases in drug therapy